Alopecia areata in pediatric patients is associated with increased rates of anxiety and depression, representing a significant psychiatric burden during adolescence.

Overview Debates Related claims Topics Sources

In England, estimated financial costs from adverse childhood experiences were £37.8 billion for mental illness and £22.7 billion for smoking, while in Wales each accounted for £1.8 billion.

The American College of Obstetricians and Gynecologists noted that more than one in three perimenopausal and postmenopausal women report depressive symptoms

The Treatment-Resistant Depression Awareness Day campaign is supported by the National Alliance on Mental Illness, Mental Health America, and the Depression and Bipolar Support Alliance.

Compass Pathways announced the establishment of the first Treatment-Resistant Depression Awareness Day in the U.S. on October 14, 2026.

Treatment-resistant depression is estimated to affect approximately 4 million people in the U.S., with fewer than 5% receiving a treatment indicated for the condition.

A survey commissioned by Compass Pathways revealed that nearly two in three caregivers report treatment-resistant depression impacts family health, with over half experiencing a major toll on their own mental health.

A survey commissioned by Compass Pathways found that nearly 95% of individuals living with treatment-resistant depression describe themselves as functioning but struggling, surviving day-to-day, or barely getting by.

Vanda Pharmaceuticals put the VQW-765 development program on hold while conducting a review of the complete VQW-765 trial dataset

Vanda Pharmaceuticals' experimental drug VQW-765 failed to achieve its primary goal of reducing social anxiety compared to placebo during a public-speaking stress test in a Phase 3 trial announced on October 14, 2026

Vanda Pharmaceuticals placed its VQW-765 social anxiety disorder program on hold following the Phase 3 trial failure announced on October 14, 2026

Shares of Vanda Pharmaceuticals fell by approximately 17% in extended trading following the October 14, 2026 announcement of the VQW-765 trial failure

The Phase 3 trial for VQW-765, announced on October 14, 2026, enrolled 546 adults with social anxiety disorder across approximately 30 trial sites in the United States

The Phase 3 trial results for VQW-765 failed to confirm findings from an earlier mid-stage trial of VQW-765 that had suggested the drug could reduce social anxiety symptoms

Vanda Pharmaceuticals designed the Phase 3 study, announced on October 14, 2026, to confirm earlier mid-stage trial results for VQW-765 in patients with social anxiety disorder

Canada should exclude mental illness as a sole condition for medically assisted dying

Describing menopause as a physiological cliff causes unnecessary patient anxiety

Outro plans to use its $7 million in capital to expand its network of deprescribing clinicians and develop artificial intelligence clinical decision support tools.

Approximately one in six Americans take an antidepressant medication, and average duration of use has surpassed five years.

Outro's deprescribing platform incorporates personalized hyperbolic tapering plans, compounded medication doses, patient monitoring, and specially-trained clinicians.

Outro plans to expand its tapering model into additional medication classes beyond antidepressants, including benzodiazepines, gabapentinoids, and GLP-1s.